Immatics

Immatics is a biopharmaceutical company focused on developing targeted immunotherapies to treat cancer, particularly solid tumors. The company's key technologies include adoptive cell therapies, next-generation ACT, TCR bispecifics, and manufacturing processes aimed at enhancing the effectiveness of T cell responses against cancer targets. Immatics collaborates with global leaders in the pharmaceutical industry and emphasizes advancing its product pipeline to improve the lives of cancer patients. The company is publicly traded and actively involved in various clinical trials and collaborations to advance cancer immunotherapy science.